CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Chen, Yu Syuan ^a   Wu, Meng Ju ^a   Huang, Chih Yang ^b,c   Lin, Shu Chun ^a   Chuang, Tsung Hsien ^d   Yu, Cheng Chia ^a,e,f   Lo, Jeng Fan ^a,b,g  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^f CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL ACTIVITY; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL RENEWAL; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; XENOTRANSPLANTATION;

ANIMALS; ANTIGENS, CD; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CLONE CELLS; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE KNOCKDOWN TECHNIQUES; GLYCOPROTEINS; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; PEPTIDES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; SRC-FAMILY KINASES;

EID: 82155192617     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028053     Document Type: Article

References (59)

1. Haddad RI, Shin DM, (2008) Recent advances in head and neck cancer. N Engl J Med 359: 1143-1154.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
3. Gupta PB, Chaffer CL, Weinberg RA, (2009) Cancer stem cells: mirage or reality? Nat Med 15: 1010-1012.
4. Visvader JE, Lindeman GJ, (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
5. Baumann M, Krause M, Hill R, (2008) Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8: 545-554.
6. Lo JF, Yu CC, Chiou SH, Huang CY, Jan CI, et al. (2011) The epithelial-mesenchymal transition mediator S100A4 maintains cancer-initiating cells in head and neck cancers. Cancer Res 71: 1912-1923.
7. Chen C, Wei Y, Hummel M, Hoffmann TK, Gross M, et al. (2011) Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One 6: e16466.
8. Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, et al. (2008) Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 14: 4085-4095.
9. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, et al. (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 104: 973-978.
10. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, et al. (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012.
11. Yin S, Li J, Hu C, Chen X, Yao M, et al. (2007) CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120: 1444-1450.
12. Chu P, Clanton DJ, Snipas TS, Lee J, Mitchell E, et al. (2009) Characterization of a subpopulation of colon cancer cells with stem cell-like properties. Int J Cancer 124: 1312-1321.
13. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396-401.
14. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, et al. (2008) The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 68: 9703-9711.
15. Rappa G, Fodstad O, Lorico A, (2008) The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 26: 3008-3017.
16. Tirino V, Desiderio V, d'Aquino R, De Francesco F, Pirozzi G, et al. (2008) Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One 3: e3469.
17. Zito G, Richiusa P, Bommarito A, Carissimi E, Russo L, et al. (2008) In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. PLoS One 3: e3544.
18. Wu MJ, Jan CI, Tsay YG, Yu YH, Huang CY, et al. (2010) Elimination of head and neck cancer initiating cells through targeting glucose regulated protein78 signaling. Mol Cancer 9: 283.
19. Beier D, Wischhusen J, Dietmaier W, Hau P, Proescholdt M, et al. (2008) CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol 18: 370-377.
20. Wang Q, Chen ZG, Du CZ, Wang HW, Yan L, et al. (2009) Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer. Histopathology 55: 284-293.
21. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, et al. (2008) Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14: 123-129.
22. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA, (2009) Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 119: 1438-1449.
23. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
24. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, et al. (2010) Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 5: e12445.
25. Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY, et al. (2010) Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 12: 982-992.
26. Guarino M, (2010) Src signaling in cancer invasion. J Cell Physiol 223: 14-26.
27. Nagaharu K, Zhang X, Yoshida T, Katoh D, Hanamura N, et al. (2011) Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells. Am J Pathol 178: 754-763.
28. Boivin D, Labbe D, Fontaine N, Lamy S, Beaulieu E, et al. (2009) The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases. Biochemistry 48: 3998-4007.
29. Takahashi K, Kanazawa H, Akiyama Y, Tazaki S, Takahara M, et al. (1989) Establishment and characterization of a cell line (SAS) from poorly differentiated human squamous-cell carcinoma of the tongue. J Jpn Stomatol Soc 38: 20-28.
30. Yang SC, Lin SC, Chiang WF, Yen CY, Lin CH, et al. (2003) Areca nut extract treatment elicits the fibroblastoid morphological changes, actin re-organization and signaling activation in oral keratinocytes. J Oral Pathol Med 32: 600-605.
31. Zhang Q, Shi S, Yen Y, Brown J, Ta JQ, et al. (2009) A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett.
32. Harper LJ, Piper K, Common J, Fortune F, Mackenzie IC, (2007) Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med 36: 594-603.
33. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, et al. (2008) Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10: 295-305.
34. Mandal M, Myers JN, Lippman SM, Johnson FM, Williams MD, et al. (2008) Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 112: 2088-2100.
35. Fujimoto M, Fujimoto Y, Poe JC, Jansen PJ, Lowell CA, et al. (2000) CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 13: 47-57.
36. Dong L, Qi N, Ge RM, Cao CL, Lan F, et al. (2010) Overexpression of CD133 promotes the phosphorylation of Erk in U87MG human glioblastoma cells. Neurosci Lett 484: 210-214.
37. Rosen JM, Jordan CT, (2009) The increasing complexity of the cancer stem cell paradigm. Science 324: 1670-1673.
38. Dalerba P, Cho RW, Clarke MF, (2007) Cancer stem cells: models and concepts. Annu Rev Med 58: 267-284.
39. Jordan CT, Guzman ML, Noble M, (2006) Cancer stem cells. N Engl J Med 355: 1253-1261.
40. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, et al. (2006) Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339-9344.
41. Mizrak D, Brittan M, Alison MR, (2008) CD133: molecule of the moment. J Pathol 214: 3-9.
42. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
43. Kelly SE, Di Benedetto A, Greco A, Howard CM, Sollars VE, et al. (2010) Rapid selection and proliferation of CD133+ cells from cancer cell lines: chemotherapeutic implications. PLoS One 5: e10035.
44. Elsaba TM, Martinez-Pomares L, Robins AR, Crook S, Seth R, et al. (2010) The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer. PLoS One 5: e10714.
45. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, et al. (2009) Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8: 806-823.
46. Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, et al. (2010) Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 70: 10433-10444.
47. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, et al. (2008) Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 3: e2637.
48. Harris AL, (2002) Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47.
49. Sun X, Wei L, Chen Q, Terek RM, CXCR4/SDF1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression. Mol Cancer 9: 17.
50. Keith B, Simon MC, (2007) Hypoxia-inducible factors, stem cells, and cancer. Cell 129: 465-472.
51. Mazumdar J, Dondeti V, Simon MC, (2009) Hypoxia-inducible factors in stem cells and cancer. J Cell Mol Med.
52. Das B, Tsuchida R, Malkin D, Koren G, Baruchel S, et al. (2008) Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 26: 1818-1830.
53. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, et al. (2009) Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 28: 3949-3959.
54. McCord AM, Jamal M, Shankavaram UT, Lang FF, Camphausen K, et al. (2009) Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 7: 489-497.
55. Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, et al. (2009) mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res 69: 7160-7164.
56. Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM, et al. (2006) HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 20: 557-570.
57. Li Z, Bao S, Wu Q, Wang H, Eyler C, et al. (2009) Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15: 501-513.
58. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY, (2008) CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27: 1749-1758.
59. Tabu K, Kimura T, Sasai K, Wang L, Bizen N, et al. (2010) Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks. Mol Cancer 9: 39.